25 - Managing Infection in the Era of MDR, XDR and PDR Among Immunocompromised Hosts

Thursday, October 17, 2024

10:30 AM – 11:45 AM US PT

Location: Petree C

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Tessa Andermann, MD, MPH (she/her/hers)

Assistant Professor of Medicine
Medicine/Division of Infectious Diseases
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States
Murat Akova, Prof. (he/him/his)

Professor
Hacettepe University
Ankara, Ankara, Turkey

Faculty(s)

Sarah Doernberg, MD, MAS (she/her/hers)

Professor
University of California, San Francisco
San Francisco, CA, United States
Carlota Gudiol, MD, PhD (she/her/hers)

Head of the Infectious Diseases Department
Bellvitge University Hospital
Barcelona, Catalonia, Spain
Malgorzata Mikulska, MD, PhD (she/her/hers)

Associate Professor
University of Genova, Italy

Disclosure(s):

Tessa Andermann, MD, MPH: No financial relationships to disclose

Murat Akova, Prof.: No financial relationships to disclose

Sarah B. Doernberg, MD, MAS: Basilea Pharmaceutica: Grant/Research Support; F2G Limited: Grant/Research Support; Genentech: Advisor/Consultant; Gilead Biosciences: Grant/Research Support; Janssen/J+J: Advisor/Consultant; Pfizer, Inc: Grant/Research Support; Regeneron, Inc: Grant/Research Support; Shinogi: Grant/Research Support

Carlota Gudiol, MD, PhD: No financial relationships to disclose

Malgorzata Mikulska, MD, PhD: AlloVir: Advisor/Consultant (Terminated, June 30, 2023); Gilead: Grant/Research Support (Ongoing), Honoraria (Ongoing); Janssen: Honoraria (Ongoing); Moderna: Honoraria (Terminated, September 16, 2023); Mundipharma: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Pfizer, Inc.: Honoraria (Terminated, April 14, 2024); Shionogi: Honoraria (Terminated, December 2, 2023)

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify the impact of antimicrobial resistance and treat appropriately the bacterial infection in immunocompromised patients;
explain appropriate empirical antibacterial regimens in the same patient groups;
describe and identify the patient groups for antibacterial prophylaxis;
apply antibacterial stewardship principles in making bacterial infections in the immunocompromised host.

Presentations:

10:30 AM – 10:55 AM US PT

The impact of antimicrobial resistance in patients with hematological malignancies and hematopoietic stem cell transplant recipients
Speaker: Sarah B. Doernberg, MD, MAS (she/her/hers) – University of California, San Francisco
10:55 AM – 11:20 AM US PT

Is it time to re-design the empiric antibacterial approach in febrile neutropenia?
Speaker: Carlota Gudiol, MD, PhD (she/her/hers) – Bellvitge University Hospital
11:20 AM – 11:45 AM US PT

Quinolone prophylaxis: a double-edged sword?
Speaker: Malgorzata Mikulska, MD, PhD (she/her/hers) – University of Genova